SCHEMBL15913480

SCHEMBL15913480

CC(C)Oc1c(Cl)ccc(-c2cnc(N)cn2)c1F

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 20/20 0.62
ALOX5AP P20292 19/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15917303 0.80 FEN1 (0.56) FEN1ALOX5AP
SCHEMBL13728902 0.77 ALOX5AP (0.46) FEN1ALOX5AP
SCHEMBL15912708 0.77 FEN1 (1.00) FEN1ALOX5AP
SCHEMBL15912845 0.76 FEN1 (1.00) FEN1ALOX5AP
SCHEMBL15912692 0.71 FEN1 (1.00) FEN1ALOX5AP
SCHEMBL15912858 0.70 ALOX5AP (0.51) FEN1ALOX5AP
SCHEMBL15915227 0.69 FEN1 (1.00) FEN1ALOX5AP
SCHEMBL15913012 0.69 FEN1 (1.00) FEN1ALOX5AP
SCHEMBL15913179 0.69 FEN1 (0.64) FEN1ALOX5AP
SCHEMBL15924908 0.69 FEN1 (0.78) FEN1ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2951169-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-08-28 EP disclosed
US-9926333-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2018-03-27 US disclosed
US-20170327514-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-16 US disclosed
US-9732093-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-15 US disclosed
US-20150368270-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-24 US disclosed
EP-2951169-A1 FLAP MODULATORS Janssen Pharmaceutica, N.V. (BE) 2015-12-09 EP disclosed
US-20150252008-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-10 US disclosed
US-9073876-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 US disclosed
US-20140221310-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed
WO-2014121040-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327514-A1 FLAP MODULATORS FEN1, PGF, TBXA2R FEN1 1/4885ALOX5AP 70/4885
US-20140221310-A1 FLAP MODULATORS FEN1, PGF, PTGIS FEN1 1/4885ALOX5AP 61/4885
US-20150368270-A1 FLAP MODULATORS FEN1, PGF, TBXA2R FEN1 1/4885ALOX5AP 70/4885
US-20150252008-A1 FLAP MODULATORS FEN1, PGF, PTGIS FEN1 1/4885ALOX5AP 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.